← Back to Search

Growth Hormone Secretagogue Receptor Agonist

Unacylated Ghrelin for Diabetes Management (UAG Trial)

N/A
Waitlist Available
Research Sponsored by David Dalessio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages between 18 and 50 years, inclusive
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

UAG Trial Summary

This trial will study the effects of a hormone called unacylated ghrelin on regulating blood sugar and beta cell function in healthy subjects.

Who is the study for?
Healthy men and women aged 18-50, with a BMI of 18.5-29.9, can join this diabetes-related trial if they're not pregnant, don't have heart or liver issues, aren't on certain drugs affecting insulin sensitivity, and haven't had cancer or eating disorders. Women must use birth control.Check my eligibility
What is being tested?
The study is testing how different forms of ghrelin (a hormone) affect blood sugar control and the function of beta cells in the pancreas that make insulin. Participants will receive either combined acyl and desacyl ghrelin, acyl ghrelin alone, unacylated ghrelin or saline as a comparison.See study design
What are the potential side effects?
While specific side effects are not listed for this trial's interventions (ghrelins), common reactions to hormone therapies may include nausea, headaches, fatigue or injection site discomfort.

UAG Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old.

UAG Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
acute insulin release (AIRg)
Secondary outcome measures
Disposition index
Insulin sensitivity
glucose tolerance

UAG Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: decaylated ghrelinExperimental Treatment1 Intervention
UAG (4.0 µg/kg/hr)
Group II: combined acyl and desacyl ghrelinExperimental Treatment1 Intervention
the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
Group III: acyl ghrelinExperimental Treatment1 Intervention
AG (1.0 µg/kg/hr)
Group IV: salinePlacebo Group1 Intervention
saline

Find a Location

Who is running the clinical trial?

David DalessioLead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled
1 Trials studying Diabetes
30 Patients Enrolled for Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,357 Previous Clinical Trials
4,315,156 Total Patients Enrolled
107 Trials studying Diabetes
138,663 Patients Enrolled for Diabetes

Media Library

Unacylated Ghrelin (Growth Hormone Secretagogue Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT01531283 — N/A
Diabetes Research Study Groups: decaylated ghrelin, combined acyl and desacyl ghrelin, saline, acyl ghrelin
Diabetes Clinical Trial 2023: Unacylated Ghrelin Highlights & Side Effects. Trial Name: NCT01531283 — N/A
Unacylated Ghrelin (Growth Hormone Secretagogue Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01531283 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor accept new participants at the moment?

"As indicated on clinicaltrials.gov, this trial is no longer recruiting participants; the initial posting was made February 1st 2011 and the latest update occured November 13th 2012. However, there are presently 3 medical trials actively looking for patients to join their study."

Answered by AI

Has unacylated ghrelin been explored in other research endeavors?

"At the present moment, two clinical trials focused on unacylated ghrelin are underway with neither in Phase 3. Cincinnati is home to the majority of these experiments and three other sites are running trials for this therapy."

Answered by AI

Does this investigation include elderly individuals who are 60 years or older?

"According to the eligibility requirements of this clinical trial, potential participants must be between eighteen and fifty years old."

Answered by AI

To what demographic is this study open for participation?

"This clinical trial is actively recruiting 30 individuals suffering from diabetes that are between 18 and 50 years of age. Eligible participants will be apparently healthy men and women with a body mass index within the range of 18.5 to 29.9 kg/m2, not including premenopausal female patients who must use an appropriate method of birth control during the study duration; male subjects do not need to practice contraception for this trial."

Answered by AI

What is the aggregate number of persons participating in this medical experiment?

"This clinical trial has ceased its search for participants, as the last update was made in November 2012. For those looking to participate in other studies, there is one active medical study related to diabetes and two involving unacylated ghrelin that are currently accepting enrolment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Deacylated Ghrelin and Beta Cell Function
David Dalessio 2011. "Deacylated Ghrelin and Beta Cell Function". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01531283.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top